儿童肿瘤相关与非肿瘤相关脓毒症的临床特征与预后对比
该回顾性研究纳入上海交通大学附属儿童医院PICU收治的768例脓毒症患儿,其中肿瘤相关脓毒症135例(17.6%)。肿瘤相关组消化道、血液和皮肤软组织感染比例更高,入PICU时血红蛋白、白细胞、血小板、中性粒细胞和CD19+细胞更低,而C反应蛋白、降钙素原、CD8+细胞及IL-6、IL-8、IL-10更高,需要CRRT和IVIG支持的比例及真菌感染比例更高,器官功能障碍个数更多。肿瘤相关脓毒症住院病死率为36.3%,显著高于非肿瘤相关组的9.3%,约为其4倍。
要点
- 肿瘤相关脓毒症占PICU脓毒症患儿的17.6%,住院病死率36.3%显著高于非肿瘤相关组的9.3%。
- 肿瘤相关组更易出现消化道、血液和皮肤软组织感染,且真菌感染比例更高。
- 肿瘤相关组入PICU时血细胞减少更明显,炎症指标更高,器官功能障碍个数更多。
核心结论
- 肿瘤相关脓毒症患儿感染部位、入PICU时炎症指标和合并感染病原菌与非肿瘤相关脓毒症存在差异,住院病死率约为非肿瘤相关脓毒症的4倍。
研究设计与样本
- 回顾性总结2016年8月至2019年7月上海交通大学附属儿童医院PICU收治的768例脓毒症患儿资料,分为肿瘤相关脓毒症组(135例)与非肿瘤相关脓毒症组(633例)。
- 肿瘤相关组进一步分为血液系统肿瘤组(80例)、实体瘤组(43例)和噬血细胞综合征组(12例)。
- 采用t检验、Mann-Whitney U检验或χ²检验比较组间临床特征、主要治疗措施和住院病死率差别。
主要发现
- 肿瘤相关脓毒症占全部脓毒症患儿的17.6%(135/768)。
- 肿瘤相关组消化道感染比例43.0%(58/135)高于非肿瘤相关组28.6%(181/633),χ²=10.718,P=0.001。
- 肿瘤相关组血液感染比例29.6%(40/135)高于非肿瘤相关组17.1%(108/633),χ²=11.297,P=0.001。
- 肿瘤相关组皮肤软组织感染比例22.2%(30/135)高于非肿瘤相关组4.1%(26/633),χ²=54.013,P<0.01。
临床怎么用
- 对肿瘤相关脓毒症患儿应特别重视感染部位监测、器官功能障碍评估及及时治疗策略。
- 肿瘤相关脓毒症患儿入PICU时血细胞减少和炎症指标升高更明显,需警惕病情严重程度。
- 肿瘤相关脓毒症患儿真菌感染风险更高,住院期间应关注合并病原菌监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the clinical features and outcomes of cancer-related and non-cancer-related sepsis in children who were admitted pediatric intensive care unit (PICU). Methods: The clinical history of patients with sepsis, who were admitted to PICU in Shanghai Children's Hospital, Shanghai Jiao Tong University from August 2016 to July 2019, were retrospectively reviewed. A total of 768 patients were divided into the cancer-related sepsis group (135 cases) and the non-cancer-related sepsis group (633 cases). The patients in the cancer-related group were further categorized into three subgroups including hematological malignancy (80 cases), solid tumor (43 cases) and hemophagocytic lymphohistiocytosis (HLH) (12 cases). The variables of clinical features, laboratory tests, pathogens, management strategies and in-hospital mortality were compared between the two groups by student t test, Mann-Whitney U test or Chi-square test. Results: The patients with cancer-related sepsis accounted for 17.6% of all patients (135/768). Regarding the site of initial infection, the incidence of gastrointestinal infection (43.0% (58/135) vs. 28.6% (181/633), χ(2)=10.718, P=0.001), blood stream infection (29.6% (40/135) vs. 17.1% (108/633), χ(2)=11.297, P=0.001) and skin and soft tissue infection (22.2% (30/135) vs. 4.1% (26/633), χ(2)=54.013, P<0.01) were higher in the patients with cancer-related sepsis than in those with non-cancer-related sepsis. On first PICU admission, the levels of hemoglobin (71 (61, 83) vs. 106 (92, 116) g/L, Z=13.594, P<0.01), white blood cell (1.4 (0.3, 5.2) vs. 9.8 (5.8, 15.1)×10(9)/L, Z=11.213, P<0.01), platelet count (51 (15, 121) vs. 286 (192, 384)×10(9)/L, Z=13.336, P<0.01), CD19(+)cells (0.106 (0.008, 0.274) vs. 0.325 (0.224, 0.454), Z=6.555, P<0.01), and neutrophil (0.449 (0.170, 0.730) vs. 0.683 (0.537, 0.800), Z=5.974, P<0.01) were significantly lower in patients with cancer-related sepsis; however, the levels of C-reactive protein (82 (25, 155) vs. 36 (11, 86) mg/L, Z=-5.257, P<0.01), procalcitonin (1.5 (0.3, 12.0) vs. 0.8 (0.2, 4.0) μg/L, Z=-2.767, P=0.006), CD8(+)cells (0.329 (0.253, 0.514) vs. 0.209 (0.156, 0.275), Z=-5.699, P<0.01), interleukin (IL) -6 (0.1 (0.1, 522.4) vs. 0.1 (0.1, 0.1) ng/L, Z=-2.747, P=0.006), IL-8 (0.1 (0.1, 177.0) vs. 0.1 (0.1, 4.5) ng/L, Z=-2.087, P=0.037), and IL-10 (0.1 (0.1, 42.7) vs. 0.1 (0.1, 6.6) ng/L, Z=-2.148, P=0.032) were significantly higher in patients with cancer-related sepsis. Similarly, the rate of continuous renal replacement therapy (CRRT) (34.8% (47/135) vs. 16.9% (107/633), χ(2)=26.267, P<0.01) and the use of intravenous immunoglobulin (IVIG) (83.0% (112/135) vs. 66.2% (419/633), χ(2)=14.667, P<0.01) were significantly higher in cancer-related sepsis group. Moreover, the incidence of co-infection with fungi was also higher in cancer-related sepsis group (14.1% (19/135) vs. 0.5%(3/633), χ(2)=73.965, P<0.01), and so was the number of multiple organ dysfunction (3 (2, 5) vs. 2 (1, 3), Z=-6.988, P<0.01). Finally, the in-hospital mortality rate of cancer-related sepsis and non-cancer-related sepsis were 36.3% (49/135) and 9.3% (59/633), respectively, also significantly different (χ(2)=67.000, P<0.01). There was no difference in the in-hospital mortality among children with hematologic tumors, solid tumors and HLH (35.0% (28/80) vs. 32.6% (14/43) vs. 7/12, χ(2)=2.838, P=0.242). Conclusions: The site of initial infection, inflammatory markers on PICU admission, and co-infection pathogen during hospitalization are different between patients with cancer-related sepsis and non-cancer-related sepsis. Besides, the in-hospital mortality of cancer-related sepsis is about 4-fold that of non-cancer-related sepsis. The monitoring of clinical features and organ dysfunction, and timely treatment are crucial for cancer-related sepsis. 目的: 对比分析儿童肿瘤相关与非肿瘤相关脓毒症的临床特征与预后。 方法: 回顾性总结2016年8月至2019年7月上海交通大学附属儿童医院儿童重症监护病房(PICU)收治的768例脓毒症患儿资料,根据是否存在肿瘤性疾病,分为肿瘤相关脓毒症组(135例)与非肿瘤相关脓毒症组(633例);前者又根据肿瘤类型分为血液系统肿瘤组(80例)、实体瘤组(43例)和噬血细胞综合征组(12例)。采用t检验、非参数检验(Mann-WhitneyU检验)或χ(2)检验比较组间临床特征、主要治疗措施和住院病死率差别。 结果: 768例脓毒症患儿中,肿瘤相关脓毒症患儿135例,占17.6%。肿瘤相关脓毒症组消化道感染比例[43.0%(58/135)比28.6%(181/633),χ(2)=10.718,P=0.001]、血液感染[29.6% (40/135)比17.1%(108/633), χ(2)=11.297,P=0.001]、皮肤软组织感染[22.2%(30/135)比4.1%(26/633), χ(2)=54.013,P<0.01]明显高于非肿瘤相关脓毒症组;肿瘤相关脓毒症组患儿入PICU后首次血红蛋白[71(61,83)比106 (92,116) g/L, Z=13.594, P<0.01]、白细胞计数[1.4(0.3,5.2)比9.8(5.8,15.1)×10(9)/L,Z=11.213,P<0.01]、血小板计数[51(15,121)比286(192,384)×10(9)/L,Z=13.336, P<0.01]、中性粒细胞[0.449(0.170,0.730)比0.683(0.537,0.800),Z=5.974,P<0.01]和CD19(+)细胞[0.106(0.008,0.274)比0.325(0.224,0.454), Z=6.555, P<0.01]明显低于非肿瘤相关脓毒症组,差异均有统计学意义;C反应蛋白[82(25,155)比36(11,86) mg/L,Z=-5.257, P<0.01]、降钙素原[1.5(0.3,12.0)比0.8(0.2,4.0) μg/L, Z=-2.767,P=0.006]、CD8(+)细胞[0.329(0.253,0.514)比0.209(0.156,0.275), Z=-5.699, P<0.01]、白细胞介素(IL)-6[0.1(0.1,522.4)比0.1(0.1,0.1)ng/L,Z=-2.747,P=0.006]、IL-8[0.1(0.1,177.0)比0.1(0.1,4.5)ng/L,Z=-2.087, P=0.037]、IL-10[0.1(0.1,42.7)比0.1(0.1,6.6)ng/L, Z=-2.148, P=0.032]明显高于非肿瘤相关脓毒症患儿组,差异均有统计学意义。肿瘤相关脓毒症组需要连续性肾替代治疗(CRRT)[34.8%(47/135)比16.9%(107/633), χ(2)=26.267,P<0.01]和静脉注射人免疫球蛋白[83.0%(112/135)比66.2%(419/633), χ(2)=14.667,P<0.01]支持的比例均高于非肿瘤相关脓毒症组。住PICU期间,肿瘤相关脓毒症患儿发生真菌感染比例高于非肿瘤相关脓毒症[14.1%(19/135)比0.5%(3/633),χ(2)=73.965,P<0.01];器官功能障碍个数多于非肿瘤相关脓毒症组[3(2,5)比2(1,3)个,Z=-6.988,P<0.01]。肿瘤相关与非肿瘤相关脓毒症患儿的住院病死率分别为36.3%(49/135)和9.3% (59/633),组间比较差异有统计学意义(χ(2)=67.000,P<0.01);血液系统肿瘤、实体肿瘤与噬血细胞综合征相关脓毒症病死率分别为35.0% (28/80)、32.6% (14/43)和7/12,组间比较差异无统计学意义(χ(2)=2.838,P=0.242)。 结论: 肿瘤相关脓毒症患儿的感染部位、入PICU时炎症指标和合并感染病原菌与非肿瘤相关脓毒症存在差异。肿瘤相关脓毒症患儿病死率为非肿瘤相关脓毒症的4倍,应特别重视肿瘤性疾病合并感染的监测、评估及治疗策略。.
引用
- Zhou TL, Zhou YP, Zhang YC, et al. [Clinical features and outcomes of cancer-related versus non-cancer-related sepsis in pediatric intensive care unit]. Zhonghua Er Ke Za Zhi. 2020. PMID: 32521960. doi:10.3760/cma.j.cn112140-20200211-00074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。